William Blair partner and biotech research analyst Andy Hsieh, Ph.D., believes the radiopharmaceuticals industry represents one of the most compelling secular growth opportunities in biotech in the next three to five years. Illuminating the Road Less Traveled in Biotech: Radiopharmaceuticals—Fifth Edition, published September 1, 2026, examines how the field may be approaching an inflection point as radiopharmaceuticals move from a niche modality toward a more central role in cancer treatment.
As the market continues to grow, we aim to provide a yearly update on radiopharmaceuticals to serve as a resource for investors seeking to understand this rapidly evolving space, which has attracted significant investment. This edition focuses on financings, recent and upcoming clinical data updates, and the current landscape of radiopharmaceutical companies and related assets.
To learn more about William Blair’s biotech equity research, contact us or your William Blair representative.